创新药概念股午后持续拉升，诺思格20cm涨停，普蕊斯、康芝药业涨超10%，泰格医药、康龙化成、 贝达药业涨幅居前。 ...

Group 1 - The core viewpoint of the news is that as of October 28, 2025, institutional investors hold a significant portion of Northstar's A-shares, totaling 71.78 million shares, which represents 74.32% of the company's total equity [1] - The top ten institutional investors collectively own 72.43% of the shares, with an increase of 2.73 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, Hongta Hongtu Medical Selected Stock Initiation A, increased its holdings slightly, while two new public funds disclosed their holdings, including Nuoan Pioneer Mixed A and Xin'ao Enjoy Life Mixed A [2] - The social security fund sector saw an increase in holdings from the National Social Security Fund 413 Combination, with a holding increase of 0.80%, and one new disclosure from the National Social Security Fund 601 Combination [2] - In terms of foreign investment, there was one foreign institution, Hong Kong Central Clearing Limited, that did not disclose its holdings in the current period [2]

Core Insights - The company reported a revenue of 227,707,628.96 yuan for the third quarter of 2025, representing a year-on-year growth of 24.48% [2] - The net profit attributable to shareholders of the listed company was 34,450,734.90 yuan, showing a year-on-year increase of 32.98% [2] Financial Performance - Revenue for Q3 2025: 227.71 million yuan, up 24.48% year-on-year [2] - Net profit for Q3 2025: 34.45 million yuan, up 32.98% year-on-year [2]

Core Viewpoint - Norsg (301333.SZ) reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, indicating positive financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 607 million yuan, representing an 8.09% year-on-year growth [1] - The net profit attributable to shareholders of the listed company was 95.5668 million yuan, showing a year-on-year increase of 13.21% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.3334 million yuan, reflecting a year-on-year growth of 22.47% [1] - Basic earnings per share stood at 1 yuan [1]

Core Insights - The company reported a revenue of 607 million yuan for the first three quarters of 2025, representing an 8.09% year-on-year increase [1] - The net profit attributable to shareholders was 95.57 million yuan, up 13.21% year-on-year, while the net profit excluding non-recurring items was 81.33 million yuan, reflecting a 22.47% increase [1] - The basic earnings per share stood at 1.00 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 35.61%, a decrease of 3.58 percentage points year-on-year, while the net profit margin was 15.94%, an increase of 0.66 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 32.74%, down 4.61 percentage points year-on-year and 5.26 percentage points quarter-on-quarter; the net profit margin was 15.50%, up 1.14 percentage points year-on-year but down 1.49 percentage points from the previous quarter [2] - Total operating expenses for Q3 2025 were 114 million yuan, a decrease of 20.86 million yuan year-on-year, with an expense ratio of 18.82%, down 5.23 percentage points year-on-year [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 8,734, a decrease of 1,686 or 16.18% from the end of the first half of the year; the average market value per shareholder increased by 37.25% from 443,100 yuan to 608,200 yuan [2] Business Overview - The company, established on August 22, 2008, and listed on August 2, 2022, is located in Haidian District, Beijing, and specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [3] - The revenue composition of the main business includes: 39.25% from clinical trial operation services, 34.10% from clinical trial site management services, 13.30% from data management and statistical analysis services, 8.45% from biological sample testing services, 3.74% from clinical pharmacology services, and 1.16% from clinical trial consulting services [3] - The company belongs to the pharmaceutical and biotechnology industry, specifically in medical services and medical research outsourcing [3]

证券代码：301333 证券简称：诺思格 公告编号：2025-046 诺思格（北京）医药科技股份有限公司 第四届监事会第十一次会议决议公告 二、监事会会议审议情况 （一）审议通过《关于<2025年第三季度报告全文>的议案》 表决情况：3票同意；0票弃权；0票反对。 经审议，监事会认为：公司《2025年第三季度报告》内容真实、准确、完整 地反映了公司2025年第三季度经营的实际情况，不存在虚假记载、误导性陈述或 者重大遗漏。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《2025年第三季度报告》（公告编号：2025-047）。 三、备查文件 1、第四届监事会第十一次会议决议。 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第四届监事会 第十一次会议于2025年10月28日在公司会议室以现场结合通讯方式召开。会议通 知已于2025年10月23日以电子邮件及专人送达等方式送达全体监事。本次会议应 出席监事3人，实际出席监事3人。会议由监事会 ...

证券代码：301333 证券简称：诺思格 公告编号：2025-045 诺思格（北京）医药科技股份有限公司 二、董事会会议审议情况 （一）审议通过《关于<2025年第三季度报告全文>的议案》 表决情况：9票同意；0票弃权；0票反对。 经审议，董事会认为：公司《2025年第三季度报告》内容真实、准确、完整 地反映了公司2025年第三季度经营的实际情况，不存在虚假记载、误导性陈述或 者重大遗漏。 公司董事会审计委员会审议通过了该议案。 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第五届董事会 第十四次会议（以下简称"本次会议"）于2025年10月28日在公司会议室以现场 结合通讯方式召开。会议通知已于2025年10月23日以电子邮件及专人送达等方式 送达全体董事。本次会议应出席董事9人，实际出席董事9人。会议由董事长WU JIE（武杰）先生主持，会议的召开符合有关法律、法规、规章和《诺思格（北 京）医药科技股份有限公司章程》（以下简称《公司章程》）的规 ...

诺思格（北京）医药科技股份有限公司 2025 年第三季度报告 证券代码：301333 证券简称：诺思格 公告编号：2025-047 诺思格（北京）医药科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 诺思格（北京）医药科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 适用 □不适用 | | | | 单位：元 | | --- | --- | --- | --- | | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | 非流动性资产处置损益（包 | | | | | 括已计提资产减值准备的冲 | -9,336.55 | -9,336.55 ...

证券代码：301333 证券简称：诺思格 公告编号：2025-044 2025 年 7 月 1 日，公司发布《关于回购公司股份期限届满暨回购完成的公 告》，截至 2025 年 6 月 30 日，公司通过回购专用证券账户以集中竞价交易方式 已累计回购公司股份 1,442,000 股，约占公司总股本 96,581,256 股的 1.49%。最 高成交价为 43.15 元/股，最低成交价为 35.06 元/股，成交总金额为 56,062,734.00 诺思格（北京）医药科技股份有限公司 关于 2025 年员工持股计划非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 诺思格（北京）医药科技股份有限公司（以下简称"公司"或"诺思格"） 于 2025 年 9 月 5 日召开第五届董事会第十三次会议及第四届监事会第十次会议， 于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会，审议通过了《关于<公司 2025 年员工持股计划（草案）>及其摘要的议案》《关于<公司 2025 年员工持股 计划管理办法>的议案》等相关议案，具体内容详见公司 ...

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]